AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1).

Nov 19, 2024 - 06:00

AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1).

Read the original article

Tags:

Previous Article

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Beta Bionics’ automated insulin delivery system picks up manufacturing partner

Beta Bionics’ automated insulin delivery system picks u...

May 26, 2023

How immuno-oncology private equity performed in the pha...

Jul 31, 2023

Vast sequencing project begins to unlock human genome’s secrets — by deciphering other mammals’ DNA

Vast sequencing project begins to unlock human genome’s...

Apr 27, 2023